The Genetic Testing Market is expected to grow at a CAGR of 11.6% from 2022–2029 to reach $43.3 billion by 2029. Genetic testing involves the analysis of chromosomes, proteins, and certain metabolites to detect heritable disease-related genotypes, mutations, phenotypes, or karyotypes for clinical purposes. Genetic testing can be done for various purposes, including diagnostic testing, prenatal testing, newborn screening, carrier testing, and preimplantation genetic diagnosis, among others. They are usually done using high throughput sequencing technology like next-generation sequencing.
Currently, a growing number of tests are being developed to analyze multiple genes that may increase or decrease a person’s risk of diseases, such as cancer or diabetes. Such tests and other applications of genomic technologies have the potential to help prevent common diseases and improve the health of individuals and populations.
The growth of this market is attributed to factors such as favorable government initiatives for promoting genetic testing, increasing prevalence of genetic disorders, increased need for early disease detection & prevention, increasing applications of genetic testing in oncology, and decreasing cost of sequencing procedures. In addition, the growing scenario of genetic direct-to-consumer genetic testing and the emerging field of genetic counseling are expected to provide significant growth opportunities for this market.
However, the factors such as the high cost of genetic testing and the social & ethical implications of genetic testing are restraining the growth of this market to a notable extent. In addition, factors such as the low chances of positive, actionable mutations and genetic data privacy & security concerns are the major challenges to the growth of this market.
Click here to: Get Free Sample Copy of this report
The outbreak of COVID-19 in March 2020 was a public health crisis and led to nationwide lockdowns and restrictions in many countries worldwide. The majority of the health services & resources were diverted to prioritizing COVID-19. Similarly, laboratory resources and skilled personnel for genetic and genomic testing were directed toward fighting the COVID-19 pandemic. The volume of genetic testing decreased during the pandemic due to growing cases of infections due to its variants like Delta and Omicron. The pandemic negatively impacted the demand for genetic testing due to the prioritization of healthcare resources for COVID-19.
The stringent lockdowns and restrictions led to supply chain disruption leading to delays in delivering the laboratory reagents and equipment. These factors impacted the growth of the market to a certain extent; however, the market is gaining traction as the situation is normalizing. Countries around the world enhanced their genomics capabilities during the pandemic to identify the spread of the virus. The COVID-19 pandemic has increased the adoption of advanced technologies such as NGS for various applications, including epidemiology, metagenomic analysis, and diagnostics. The widespread adoption of enhanced genomic technologies by many countries around the world offers a great opportunity for the genetic testing market.
Increased Genetic Testing in Oncology to Drive Market Growth
Cancer is a genome disease, and major strides have been made in understanding and treating this heterogeneous collection of diseases. This comprises the initial identification of oncogenes and tumor suppressor genes for the development of the first generation of targeted therapies, culminating in the full annotation of the genomic landscape of the most common cancer types.
The global prevalence of cancer is expected to increase from 19.2 million new cases in 2020 to 24.0 million new cases in 2030, as per International Agency for Research on Cancer. Also, the mortalities from cancer are expected to increase from 9.9 million deaths in 2020 to 12.9 million deaths in 2030. Oncology biomarkers can provide affordable, reliable, accurate, non-invasive, and sensitive information to help effectively manage cancer. Early cancer detection can lead to positive results.
Sequencing technologies like NGS are increasingly used for genetic profiling in targeted cancer therapy applications due to the decreasing costs and turnaround time of NGS, improvements in bioinformatics analyses, and the harmonization of the knowledge base to facilitate the clinical interpretation of genetic results.
Growing Direct-to-consumer Genetic Testing to Offer Growth Opportunities for the Market
Direct-to-consumer genetic testing (DCGT) allows individuals to gain a deeper understanding of their genetic information without involving their physicians. The major factor for the growth in this area is consumer awareness of the links between genetics and diseases, which enhance the evolution of patients' health and precision medicine designed around individual genetic profiles. For accurate genetic testing, companies are working to improve the detection of carrier status and ease of consumer use.
In recent years, the number of DTC genetic tests performed has increased significantly and is expected to show strong growth in the future. Moreover, growing consumer use and subsequent follow-up with healthcare providers and insurers can be further anticipated to propel the growth of DTC genetic testing.
In 2022, the Consumables & Reagents Segment to Dominate Genetic Testing Market
Based on product, the genetic testing market is segmented into consumables & reagents, instruments, and services. In 2022, the consumables & reagents segment is estimated to account for the largest share of the genetic testing market. The large share of this segment is attributed to factors such as the recurring purchase of reagents and kits, new launches of kits & reagents, and increased demand for clinical diagnostics tests for diagnostic testing, prenatal testing, newborn screening, preimplantation testing, and other applications.
In 2022, the Disease Diagnostics Segment is Estimated to Account for the Largest Share of the Genetic Testing Market
Based on test type, the genetic testing market is segmented into diagnostic testing, prenatal testing, carrier testing, newborn screening, preimplantation testing, and other test types. In 2022, the disease diagnostics segment is estimated to account for the largest share of the genetic testing market. Genetic diagnostic testing is used to diagnose or rule out a specific genetic or chromosomal condition. The large share of this segment is attributed to factors such as the increased prevalence of various chronic and rare genetic diseases, high demand for early disease diagnosis and treatment, and rapid technological developments in genetic diagnostic testing.
In 2022, the Molecular Tests Segment is Estimated to Account for the Largest Share of the Genetic Testing Market
Based on method, the genetic testing market is segmented into molecular tests, chromosomal tests, and biochemical tests. In 2022, the molecular tests segment is estimated to account for the largest share of the genetic testing market. Molecular tests vary in scope and include targeted single variant, single gene, gene panel, and whole exome sequencing/whole genome sequencing. The large market share of this segment is attributed to factors such as advancements in technology and the ability to perform sequencing at single nucleotide resolution with cheaper, faster, and with the utmost accuracy by using whole genome sequencing (WGS) and whole exome sequencing (WES) technology.
In 2022, the Hospitals & Clinics Segment is Estimated to Account for the Largest Share of the Genetic Testing Market
Based on end user, the genetic testing market is segmented into hospitals & clinics, diagnostic laboratories, academic & research institutes, and other end users. In 2022, the hospitals & clinics segment is estimated to account for the largest share of the genetic testing market. The large share of this segment is attributed to factors such as the increased utilization of advanced sequencing technologies in hospitals, increased rate of hospitalizations, increased patient preference for genomic testing, and high healthcare spending in major countries.
Asia-Pacific: The Fastest-growing Market
Asia-Pacific is slated to register the highest growth rate in the genetic testing market during the forecast period. The high market growth in Asia-Pacific is attributed to the advancing healthcare infrastructure in the region, a large patient pool coupled with the growing adoption of advanced genomics technologies, the growing prevalence of various chronic diseases, and the increasing affordability of genomic testing.
Key Players
The report includes a competitive landscape based on an extensive assessment of product portfolio, test type, method, end user, geographic presence, and the key growth strategies adopted by leading market players in the industry over the past four years.
The key players profiled in the genetic testing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), 23andMe, Inc. (U.S.), Foundation Medicine, Inc. (U.S.) (Subsidiary of Roche Holding AG), Rosetta Genomics Ltd. (U.S.), OPKO Health Inc. (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.) and Invitae Corporation (U.S.).
Genetic Testing Market, by Product & Service
Genetic Testing Market, by Test Type
Genetic Testing Market, by Method
Genetic Testing Market, by End User
Genetic Testing Market, by Geography
Key questions answered in the report:
The genetic testing market report covers the market sizes & forecasts based on product, test type, method, end user, and geography. The genetic testing market studied in this report involves the value analysis of various segments and subsegments of the genetic testing market at the regional and country levels.
The genetic testing market is projected to reach $43.3 billion by 2029, at a CAGR of 11.6% during the forecast period of 2022–2029.
The genetic testing market is segmented into consumables & reagents, instruments, and services. In 2022, the consumables & reagents segment is estimated to account for the largest share of the genetic testing market due to recurring demand for assays, reagents & consumables and high demand for genetic diagnostic testing.
The genetic testing market is segmented into diagnostic testing, prenatal testing, carrier testing, newborn screening, preimplantation testing, and other test types. In 2022, the disease diagnostics segment is estimated to account for the largest share of the genetic testing market due to the high prevalence of various chronic diseases, increased demand for early disease diagnosis, and increased awareness among patients.
The genetic testing market is segmented into molecular tests, chromosomal tests, and biochemical tests. In 2022, the molecular tests segment is estimated to account for the largest share of the genetic testing market due to high accuracy, wide applicability, and ability to perform sequencing at a single nucleotide level.
The genetic testing market is segmented into hospitals & clinics, diagnostic laboratories, academic & research institutes, and other end users. In 2022, the hospitals & clinics segment is estimated to account for the largest share of the genetic testing market due to the high number of hospitalized patients, increased preference for genetic testing, and advanced healthcare infrastructure in hospitals.
The growth of this market is attributed to factors such as favorable government initiatives for promoting Genetic testing, increasing prevalence of genetic disorders, increased need for early disease detection & prevention, increasing applications of genetic testing in oncology, and decreasing cost of sequencing procedures. In addition, the growing scenario of genetic direct-to-consumer genetic testing and the emerging field of genetic counseling are expected to provide significant growth opportunities for this market.
Factors such as the high cost of genetic testing and the social and ethical implications of genetic testing are expected to hinder the growth of this market to a notable extent. In addition, factors such as the low chances of positive, actionable mutations and genetic data privacy & security concerns are the major challenges to the growth of this market.
The key players operating in the genetic testing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), 23andMe, Inc. (U.S.), Foundation Medicine, Inc. (U.S.) (Subsidiary of Roche Holding AG), Rosetta Genomics Ltd. (U.S.), OPKO Health Inc. (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.) and Invitae Corporation (U.S.).
The Asia-Pacific region is slated to witness the highest growth rate during the forecast period and offer significant growth opportunities for the players operating in this market. The high market growth in Asia-Pacific is attributed to factors such as the large patient pool, advancing healthcare infrastructure, increasing disposable income of the patients, rising prevalence of chronic diseases, and accelerating economic growth of many countries in this region.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Favorable Government Initiatives for Promoting Genomics
4.2.2. Increasing Prevalence of Genetic Disorders
4.2.3. Increased Need for Early Disease Detection & Prevention
4.2.4. Increasing Applications of Genetic Testing in Oncology
4.2.5. Decreasing Cost of Sequencing Procedures
4.3. Restraints
4.3.1. High Cost of Genetic Testing
4.3.2. Social and Ethical Implications of Genetic Testing
4.4. Opportunities
4.4.1. Growing Scenario of Genetic Direct-to-Consumer Genetic Testing
4.4.2. Emerging Field of Genetic Counseling
4.5. Challenges
4.5.1. Low Chances of Positive, Actionable Mutations
4.5.2. Genetic Data Privacy & Security Concerns
4.6. The Impact of COVID-19 on the Genetic Testing Market
5. Genetic Testing Market, by Product & Service
5.1. Introduction
5.2. Consumables & Reagents
5.3. Instruments
5.4. Services
6. Genetic Testing Market, by Test Type
6.1. Introduction
6.2. Diagnostic Testing
6.3. Prenatal Testing
6.4. Carrier Testing
6.5. Newborn Screening
6.6. Preimplantation Testing
6.7. Other Test Types
7. Genetic Testing Market, by Method
7.1. Introduction
7.2. Molecular Tests
7.3. Chromosomal Tests
7.4. Biochemical Tests
8. Genetic Testing Market, by End User
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Diagnostic Laboratories
8.4. Academic & Research Institutes
8.5. Other End Users
9. Genetic Testing Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2021)
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Thermo Fisher Scientific Inc.
11.2. Quest Diagnostics Incorporated
11.3. Illumina, Inc.
11.4. Eurofins Scientific SE
11.5. 23andMe, Inc.
11.6. Foundation Medicine, Inc. (Subsidiary of Roche Holding AG)
11.7. Rosetta Genomics Ltd.
11.8. OPKO Health Inc.
11.9. Natera, Inc.
11.10. PerkinElmer, Inc.
11.11. Myriad Genetics, Inc.
11.12. Laboratory Corporation of America Holdings
11.13. Invitae Corporation
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Genetic Testing Market Drivers: Impact Analysis (2022–2029)
Table 2 Genetic Testing Market Restraints: Impact Analysis (2022–2029)
Table 3 Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 4 Global Genetic Testing Consumables & Reagents Market Size, by Country/Region, 2020–2029 (USD Million)
Table 5 Global Genetic Testing Instruments Market Size, by Country/Region, 2022–2029 (USD Million)
Table 6 Global Genetic Testing Services Market Size, by Country/Region, 2022–2029 (USD Million)
Table 7 Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 8 Genetic Testing Market Size for Diagnostic Testing, by Country/Region, 2020–2029 (USD Million)
Table 9 Genetic Testing Market Size for Prenatal Testing, by Country/Region, 2020–2029 (USD Million)
Table 10 Genetic Testing Market Size for Carrier Testing, by Country/Region, 2022–2029 (USD Million)
Table 11 Genetic Testing Market Size for Newborn Screening, by Country/Region, 2022–2029 (USD Million)
Table 12 Genetic Testing Market Size for Preimplantation Testing, by Country/Region, 2022–2029 (USD Million)
Table 13 Genetic Testing Market Size for Other Test Types, by Country/Region, 2020–2029 (USD Million)
Table 14 Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 15 Genetic Testing Market Size for Molecular Tests, by Country/Region, 2022–2029 (USD Million)
Table 16 Genetic Testing Market Size for Chromosomal Tests, by Country/Region, 2022–2029 (USD Million)
Table 17 Genetic Testing Market Size for Biochemical Tests, by Country/Region, 2022–2029 (USD Million)
Table 18 Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 19 Genetic Testing Market Size for Hospitals & Clinics, by Country/Region, 2020–2029 (USD Million)
Table 20 Genetic Testing Market Size for Diagnostic Laboratories, by Country/Region, 2022–2029 (USD Million)
Table 21 Genetic Testing Market Size for Academic & Research Institutes, by Country/Region, 2020–2029 (USD Million)
Table 22 Genetic Testing Market Size for Other End Users, by Country/Region, 2020–2029 (USD Million)
Table 23 Genetic Testing Market Size, by Country/Region, 2020–2029 (USD Million)
Table 24 North America: Genetic Testing Market Size, by Country, 2020–2029 (USD Million)
Table 25 North America: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 26 North America: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 27 North America: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 28 North America: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 29 U.S.: Key Macroindicators
Table 30 U.S.: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 31 U.S.: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 32 U.S.: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 33 U.S.: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 34 Canada: Key Macroindicators
Table 35 Canada: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 36 Canada: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 37 Canada: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 38 Canada: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 39 Europe: Genetic Testing Market Size, by Country/Region, 2020–2029 (USD Million)
Table 40 Europe: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 41 Europe: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 42 Europe: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 43 Europe: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 44 Germany: Key Macroindicators
Table 45 Germany: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 46 Germany: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 47 Germany: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 48 Germany: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 49 France: Key Macroindicators
Table 50 France: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 51 France: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 52 France: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 53 France: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 54 U.K.: Key Macroindicators
Table 55 U.K.: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 56 U.K.: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 57 U.K.: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 58 U.K.: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 59 Italy: Key Macroindicators
Table 60 Italy: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 61 Italy: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 62 Italy: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 63 Italy: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 64 Spain: Key Macroindicators
Table 65 Spain: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 66 Spain: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 67 Spain: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 68 Spain: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 69 RoE: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 70 RoE: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 71 RoE: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 72 RoE: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 73 Asia-Pacific: Genetic Testing Market Size, by Country/Region, 2020–2029 (USD Million)
Table 74 Asia-Pacific: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 75 Asia-Pacific: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 76 Asia-Pacific: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 77 Asia-Pacific: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 78 Japan: Key Macroindicators
Table 79 Japan: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 80 Japan: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 81 Japan: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 82 Japan: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 83 China: Key Macroindicators
Table 84 China: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 85 China: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 86 China: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 87 China: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 88 India: Key Macroindicators
Table 89 India: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 90 India: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 91 India: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 92 India: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 93 RoAPAC: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 94 RoAPAC: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 95 RoAPAC: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 96 RoAPAC: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 97 Latin America: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 98 Latin America: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 99 Latin America: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 100 Latin America: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 101 Middle East & Africa: Genetic Testing Market Size, by Product, 2020–2029 (USD Million)
Table 102 Middle East & Africa: Genetic Testing Market Size, by Test Type, 2020–2029 (USD Million)
Table 103 Middle East & Africa: Genetic Testing Market Size, by Method, 2020–2029 (USD Million)
Table 104 Middle East & Africa: Genetic Testing Market Size, by End User, 2020–2029 (USD Million)
Table 105 Recent Developments, by Company (2020–2022)
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Genetic Testing Market Size, by Product, 2022 Vs 2029 (USD Million)
Figure 8 Genetic Testing Market Size, by Test Type, 2022 Vs 2029 (USD Million)
Figure 9 Genetic Testing Market Size, by Method, 2022 Vs 2029 (USD Million)
Figure 10 Genetic Testing Market Size, by End User, 2022 Vs 2029 (USD Million)
Figure 11 Genetic Testing Market Size, by Geography
Figure 12 Market Dynamics
Figure 13 Genetic Testing Market Size, by Product, 2022–2029 (USD Million)
Figure 14 Genetic Testing Market Size, by Test Type, 2022–2029(USD Million)
Figure 15 Genetic Testing Market Size, by Method, 2022–2029 (USD Million)
Figure 16 Genetic Testing Market Size, by End User, 2022-2029 (USD Million)
Figure 17 Genetic Testing Market Size, by Geography, 2022–2029 (USD Million)
Figure 18 North America: Genetic Testing Market Snapshot
Figure 19 Europe: Genetic Testing Market Snapshot
Figure 20 Asia-Pacific: Genetic Testing Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players (2020–2022)
Figure 22 Genetic Testing Market: Competitive Benchmarking Based on Product
Figure 23 Genetic Testing Market: Competitive Benchmarking Based on Test Type
Figure 24 Genetic Testing Market: Competitive Benchmarking Based on Geography
Figure 25 Market Share Analysis: Genetic Testing Market (2021)
Figure 26 Thermo Fisher Scientific Inc.: Financial Overview (2021)
Figure 27 Quest Diagnostics Incorporated: Financial Overview (2021)
Figure 28 Illumina, Inc.: Financial Overview (2021)
Figure 29 Eurofins Scientific SE: Financial Overview (2021)
Figure 30 23andMe, Inc.: Financial Overview (2021)
Figure 31 Roche Holding AG: Financial Overview (2021)
Figure 32 Rosetta Genomics Ltd.: Financial Overview (2021)
Figure 33 OPKO Health Inc.: Financial Overview (2021)
Figure 34 Natera, Inc.: Financial Overview (2021)
Figure 35 PerkinElmer, Inc.: Financial Overview (2021)
Figure 36 Myriad Genetics, Inc.: Financial Overview (2021)
Figure 37 Laboratory Corporation of America Holdings: Financial Overview (2021)
Figure 38 Invitae Corporation: Financial Overview (2021)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Jan-2023
Published Date: Jan-2023
Published Date: Jan-2023
